<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: September 23, 1997 Commission File No. 0-27352
------------------ -------
(Date of earliest event reported)
HYBRIDON, INC.
--------------
(Exact name of registrant as specified in its Charter)
Delaware 04-3072298
-------- ----------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
620 Memorial Drive, Cambridge, Massachusetts 02139
- -------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(617) 528-7000
--------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
On September 23, 1997, Hybridon, Inc. (the "Company") issued a press
release announcing that (i) the Company is moving forward with the appeal
process with The Nasdaq Stock Market Inc., in response to the notification of
delisting that the Company announced last week; and (ii) the Company's common
stock, $.001 par value per share, will continue to trade on the Nasdaq National
Market until the appeal is resolved. A copy of the press release has been filed
with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein
by reference.
ITEM 7. EXHIBITS
99.1 Press release dated September 23, 1997.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: September 24, 1997 HYBRIDON, INC.
/s/ E. Andrews Grinstead, III
---------------------------------------
E. Andrews Grinstead, III
Chairman, President and Chief Executive
Officer
<PAGE> 4
INDEX TO EXHIBITS
EXHIBIT
NO. DESCRIPTION
- ------- -----------
99.1 Press release dated September 23, 1997.
<PAGE> 1
EXHIBIT 99.1
[HYBRIDON LOGO] NEWS RELEASE
<TABLE>
<CAPTION>
Hybridon, Inc. Tel: 617.528.7000 Fax: 617.528.7001
620 Memorial Drive www.hybridon.com
<S> <C>
FOR IMMEDIATE RELEASE Cambridge, MA 02139
Contact: Douglas J. Jensen
Vice President, Administration and
Corporate Development
617.528.7523
Noonan Russo Communications, Inc.
212.695.4455
Stephanie Seiler, PhD. (Investor) ext. 212
Renee Solano (media) ext.227
</TABLE>
HYBRIDON TO CONTINUE TRADING PENDING NASDAQ APPEAL PROCESS
Cambridge, Mass. - September 23, 1997 - Hybridon, Inc. (Nasdaq: HYBN) today
announced that the Company is moving forward with the appeal process with The
Nasdaq Stock Market Inc. ("NASDAQ"), in response to a notification of delisting
which the Company announced last week. Hybridon received a letter from NASDAQ
indicating that the Company was no longer in compliance with listing
requirements and would be delisted. Hybridon has filed an appeal with NASDAQ,
and the Company's stock will continue to trade on the Nasdaq National Market
until the appeal is resolved.
"We are examining our options for addressing NASDAQ's concerns and moving
forward with our appeal process," said E. Andrews Grinstead, Chief Executive
Officer of Hybridon. "There are a number of possible approaches to resolving our
non-compliance issues, in addition to complying with alternative listing
requirements on the NASDAQ National Market which we are exploring. Hybridon
stock will continue to trade during the appeal process."
Hybridon, headquartered in Cambridge, Massachusetts, is a leader in the
discovery and development of novel genetic medicines for the treatment of
important diseases, based primarily on antisense technology. Antisense
technology involves the use of synthetic segments of DNA and RNA to stop the
production of disease-associated proteins by interacting at the genetic level
with target strands of messenger RNA.
# # #
Leadership in Genetic Antisense Medicine
